Posts

U.S. Launches Section 301 Investigation into Germany Over Drug Pricing and Unfair R&D Burden in 2026

on

Drugmakers must disclose U.S. production plans to qualify for tariff exemptions

on

Pharma Industry's Reshoring Boom: Massive Investments Amid Tariff Pressures

on

UK Finalises US Pharma Trade Deal Securing Tariff-Free Access for British Medicines

on

AstraZeneca Reaches Drug Pricing Deal with White House, Becomes Second Pharma to Do So

on

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

on

Trump’s Most Favored Nation Policy and EU Generics: Recent Developments

on

Pfizer CEO Holds 'Extremely Productive' Talks With Trump Administration Amid MFN Pricing and Tariff Threats

on

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

on

Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty

on

Sanofi Announces $20 Billion US Investment Over Five Years

on

Pfizer's Bourla is 'cautiously optimistic' on tariffs, says M&A is on the table

on

Navigating Trumps tariffs for pharma

on

Trump Tariffs Could Delay Regulatory Filings for Half of Biotech Companies

on

U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs

on